IBR   13079
INSTITUTO DE BIOLOGIA MOLECULAR Y CELULAR DE ROSARIO
Unidad Ejecutora - UE
capítulos de libros
Título:
Genetic Manipulation of Myxobacteria
Autor/es:
WESLEY P. BLACK, BRYAN JULIEN, EDUARDO RODRIGUEZ, AND ZHAOMIN YANG
Libro:
Manual of Industrial Microbiology and Biotechnology, Third Edition
Editorial:
ASM Press
Referencias:
Año: 2010; p. 262 - 272
Resumen:
Myxobacteria, a coherent group of the delta proteobacteria, are recognized as important producers of secondary metabolites of industrial and medical importance. These Gram-negative bacteria have fascinated scientists for over half a century because of their surface gliding motility and their starvation-induced muticellular development (33, 71, 81). In more recent years, they have emerged as prominent producers of secondary metabolites. Please see these references (3, 4, 17, 18, 57) for some recent reviews. Myxobacteria as a group produce the most bioactive compounds among Gram-negatives and rank 3rd among bacteria, only behind actinomycetes and bacilli (57, 58). Currently there are over 100 different known structures of natural products from myxobacteria with about 500 structural variants (3, 4). Sorangium cellulosum accounts for nearly 50% of these and Myxococcus and Stigmatella account for about 25% (17, 18). What is even more exciting is that the bioactive chemicals from myxobacteria tend to be novel and distinct (3). For example, S. cellulosum produces epothilone (26), an anti-cancer drug currently marketed as Ixempra (Bristol-Myers Sqiubb). Although epothilone acts as a microtubule stabilizer like paclitaxel (6), it remains effective against paclitaxel-resistant cancer cells (39). Genome sequences of a few myxobacteria indicated that there are genes for the biosynthesis of unidentified secondary metabolites (4, 20, 61). Considering the limited number of anti-tumor and anti-microbial compounds in the pipeline, it is imperative to further explore myxobacteria in industrial microbiology and biotechnology.